Demonstrating efficacy in patients with severe COVID-19, corticosteroids, IL-6 inhibitors, and Janus kinase inhibitors [66] have been established as agents capable of reducing mortality [57] underscoring the modifiable nature of inflammation and the potential for improvement in clinical outcomes through anti-inflammatory therapeutic interventions. Here, IL6 is linked to COVID-19.